🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Oaktree Specialty Lending Corporation (OCSL)
NASDAQ: OCSL · Real-Time Price · USD
11.77
-0.26 (-2.16%)
At close: Nov 17, 2026, 4:00 PM EST
11.74
-0.03 (-0.21%)
Pre-market: Nov 18, 2026, 8:40 AM EST
← View all transcripts

Earnings Call: Q4 2026

Nov 17, 2026

Summary

Non-accruals declined 44% YoY to $45 million, while FY26 adjusted NII fell to $1.49 per share. Leverage ended at 1.00x, with ~$689 million of pro forma liquidity and a focus on resolving non-accruals and deploying capital selectively.

Operator

Welcome, and thank you for joining Oaktree Specialty Lending Corporation's fourth fiscal quarter 2026 conference call. Today's conference is being recorded. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now turn the call over to Alison Mermey, OCSL's Head of Investor Relations. Please go ahead.

Alison Mermey
Head of Investor Relations, OCSL

Thank you, operator. Our fourth fiscal quarter and full year 2026 earnings release, which we issued this morning, along with the accompanying slide presentation, can be accessed on the investor section of our website, www.oaktreespecialtylending.com. Before we begin, I want to remind you that the comments on today's call include forward-looking statements reflecting current views with respect to, among other things, future operating results and financial performance. Actual results could differ materially from those implied or expressed in the forward-looking statements. Please refer to the relevant SEC filings for a discussion of these factors in further detail. Oaktree undertakes no duty to update or revise any forward-looking statements. I'd also like to remind you that nothing on this call constitutes an offer to sell or solicitation of an offer to purchase any interest in an Oaktree fund.

Investors and others should note that OCSL uses the investor section of its corporate website to announce material information. The company encourages investors, the media, and others to review information that it shares on its website. On today's call, Matt Pendo, President of OCSL, will begin with a progress report on fiscal 2026 priorities and an overview of our fourth fiscal quarter results. Armen Panossian, CEO and Co-Chief Investment Officer, will then provide a market update. Raghav Khanna, Co-Chief Investment Officer, will cover portfolio activity. Chris McKown, CFO and Treasurer, will close with a review of our financial results before we open the call for questions. Now I'll turn the call over to Matt Pendo, President of OCSL. Matt.

Matt Pendo
President, OCSL

Thank you, Alison, and good morning, everyone. I would like to begin by reflecting on the progress we've made against our two main priorities from this past year. Number one, reducing non-accruals, and number two, keeping our balance sheet flexible. I'll then cover our financial highlights and our dividend. Starting with non-accruals. At the end of our fiscal year, non-accruals were approximately 1.8% of the total debt portfolio at fair value. This was down about 120 basis points from a year ago and relatively unchanged from June. In dollar terms, non-accruals at fair value have fallen from $81 million a year ago to $45 million today, a reduction of 44%. Importantly, nearly 85% of the decline in non-accrual dollars over the past year came from proceeds received and investments returning to accrual status. We believe this reflects our team's ability to successfully work through challenging credits.

Raghav will walk through additional updates to non-accrual positions in his remarks. There were several positive developments to our balance sheet this quarter, including an update to our ratings outlook and a bond offering. First, in August, Moody's revised our outlook to stable and kept our Baa3 rating unchanged. Second, in September, we priced $300 million of five-year unsecured notes due 2031 with a 7% coupon and a spread of 240 basis points over U.S. Treasuries. After swapping to floating rate, the equivalent spread to SOFR is 258 basis points. This was our first bond issuance in over a year, and we were pleased with the outcome in a choppy market backdrop. Demand was strong, with the final order book more than three times the size of the deal and included new OCSL bond investors. We want to thank the fixed income community for their support on this transaction.

The incremental cost of the new financing is less than half a cent per share per quarter. After the January 2027 notes are repaid at maturity using borrowings under our revolving credit facility, we'll be left with a well-staggered maturity profile, and our next debt maturity is February 2029. We maintained conservative leverage during the quarter, ending September 30th at 1.00 net debt to equity. Over the course of fiscal year 2026, we maintained net leverage between 0.97 times and 1.07 times, well inside the long-term target range of 0.9 times to 1.25 times. Liquidity was approximately $1.04 billion at quarter end. That figure is temporarily elevated because the January notes have not yet been repaid. Pro forma for that repayment, liquidity is approximately $689 million, in line with last quarter and a year ago. Turning to financial highlights for our fourth fiscal quarter and fiscal year.

Adjusted net investment income was $29.6 million, or approximately $0.34 per share, down from $32.2 million, or $0.37 per share in the prior quarter. This decrease primarily reflected a lower average portfolio balance and a higher income base incentive fee. For the full fiscal year, adjusted net investment income was $131.7 million, or $1.49 per share, compared to $151.3 million, or $1.76 per share for the 2025 fiscal year. Now turning to the dividend. Our board declared a total cash dividend of $0.32 per share for the quarter, composed of a base cash dividend of $0.30 per share and a supplemental dividend of $0.02 per share. The dividends are payable in cash on December 31, 2026. The stockholders of record on December 15, 2026.

As a reminder, we adjusted the base dividend in May to be covered by earnings at our current conservative leverage and maintain the supplemental dividend equal to 50% of adjusted net investment income in excess of the base dividend. Dividends declared in fiscal 2026 totaled $1.39 per share, which represented 108% of adjusted net investment income. As we look to fiscal 2027, our top priorities are unchanged: resolve non-accruals, exit non-income-producing equity positions, and redeploy those proceeds into performing assets. With net leverage of 1.00 times and nearly $700 million of pro forma liquidity, we have the flexibility to be opportunistic as new investments and strategic opportunities arise. With that, I'll turn the call over to Armen to discuss the market environment.

Armen Panossian
CEO and Co-CIO, OCSL

Thank you, Matt. Since this is a fiscal year-end call, I want to compare where we stood a year ago with where we are today. Last year, the Fed had just cut rates in September and October, and the market expected additional rate cuts in 2026, along with an upswing in M&A activity. Neither of those predictions materialized. Instead, markets saw increased volatility in early 2026 amid concerns of AI disruption, geopolitical uncertainty, and renewed inflation pressures. It is a good reminder of why Oaktree's investment philosophy is tied to fundamental credit analysis rather than macro forecasting. Fast-forward to today. With Brent crude rising above $100 per barrel during the September quarter and large AI-related CapEx adding to inflation pressures, the Fed instead raised rates by 25 basis points.

That put the federal funds rate at 3.75%-4%, and the 10-year Treasury yield moved above the symbolic 5% threshold, reaching its highest level in nearly two decades. A year ago, the debate was how far rates would fall. Today, it is how long they stay high and how high. Our view is that a move in short-term base rates from approximately 4% to 5% would remain manageable and could be beneficial to investor returns, as most of the increase would flow through to net investment income. For OCSL, 91% of our debt investments are floating rate, and a higher base rate increases contractual interest income as loans reset. The other important factor is whether our borrowers can withstand higher rates. We assess each borrower's interest coverage across a range of base rate scenarios and build cushion into the capital structure at underwriting.

Based on our borrowers' last 12 months of results, weighted average interest coverage is 2.3 times. If base rates rose by 100 basis points, coverage would still be about 2.1 times, above the roughly 1.9 times trough our portfolio experienced in late 2023 and early 2024. Against the change in the rate backdrop, credit market outcomes in the quarter were uneven. U.S. leveraged loans returned nearly 2%, supported by floating rate coupons that limit sensitivity to rising rates, while high-yield bonds declined by almost 2% as Treasury yields rose. Corporate fundamentals remained broadly resilient, but the weakest leverage credits lagged, reflecting increasingly selective investor appetite and the growing strain of elevated borrowing costs. On deal activity, direct lending volume rebounded slightly in September, although year-to-date deal flow and average deal size remained below that of last year.

Capital is still competitive for most transactions, despite a pullback for many of the largest non-traded BDCs, meaning supply and demand are relatively balanced. Spreads on new sponsor-backed first lien loans held at SOFR plus 500 to 550 basis points for several months, about 50 to 100 basis points wider than that at the end of 2025. As the broadly syndicated loan market continued to tighten in the quarter, the premium that direct lending new originations offered over new broadly syndicated loans widened to over 150 basis points. Putting it together, we remain focused on what we can control, and we feel well-positioned even in a higher-for-longer and more volatile environment. With that, I will turn the call over to Raghav for a review of our investment activity and portfolio.

Raghav Khanna
Co-CIO, OCSL

Thank you, Armen. I will start with new originations and exits, then discuss non-accruals before closing with portfolio metrics. Turning to originations, new investment commitments totaled $179 million in the quarter, compared with $206 million last quarter and $208 million in the fourth fiscal quarter of 2025. We have seen our pipeline build steadily since late September and originated about $80 million of new investment commitments in October. Weighted average yield on new debt investments during the quarter was 9.6%, with a spread on new originations of about 570 basis points, wider than the market spread range of 500 to 550. One notable deal during the quarter was a first lien loan to Outcomes First Group, which appears as OFS Bidco on our schedule of investments. Outcomes First Group is the U.K.'s largest independent provider of schools for children and youth with special educational needs and disabilities.

The total facility consisted of GBP 600 million of first lien debt, with about 75% funded upfront, priced at SONIA + 525 basis points with 1.5 points of OID. The transaction refinanced the company's existing debt and supports further expansion, including internationally. Oaktree's longstanding relationship with the sponsor, PPG, positioned Oaktree as the anchor lender. The investment was underwritten and structured by our European private debt team that has deep local market knowledge and direct engagement with the management team. We like the company due to its long operating history, hard-to-replicate footprint, high quality of schools, and strong revenue visibility. It also operates in an industry with several demand tailwinds that includes statutory funding obligations, a persistent structural supply shortage, and high barriers to entry. This deal demonstrates the value of combining on-the-ground presence and regional expertise with global relationships.

During the quarter, we also participated in three performing equity investments that increased our equity exposure to 5.5% of fair value from 3.9% last quarter. These income-producing equity deals are highly structured with negotiated downside protection and offer compelling risk-adjusted returns for our portfolio. Moving now to exits and prepayments. Proceeds from prepayments, exits, other paydowns, and sales were $198 million, compared with $263 million last quarter and $177 million last year. We were repaid in full on several private investments during the quarter. Some borrowers were taken out in the broadly syndicated loan market, and some were refinanced by other private lenders. A notable exit in the quarter was the repayment of our first lien term loan in RumbleOn, which appeared in our schedule of investments as RideNow Group, a publicly traded company that operates power sports retail dealerships and an e-commerce business.

We were the agent on the term loan, which originally funded in 2021 to finance RumbleOn's acquisition of the RideNow power sports platform. Integration challenges and weaker post-COVID consumer spending pressured EBITDA and put covenant compliance at risk, leading us to mark the loan down to 94 in the year 2023. Importantly, our highly structured loan prevented value leakage during the company's period of underperformance, and we worked collaboratively with the company on a turnaround plan involving new management, cost reductions, asset sales, and capital raises. These actions repositioned the company for growth, and we were willing to provide relief to the company in the form of covenant resets and a maturity extension in exchange for debt paydowns during this time to rightsize the balance sheet.

In September, RumbleOn refinanced its term loan, and our remaining $35 million position was repaid at 101, including an exit fee, a year ahead of the 2027 maturity. This is another example of how our focused structuring capabilities, patience, collaboration with management teams, and discipline yielded a positive outcome for OCSL stakeholders. Turning to non-accruals. At September 30th, six companies were on non-accrual, the same as last quarter and down from 10 a year ago. Non-accruals represented approximately 1.8% of the total debt portfolio at fair value. This also represents 4% of the total debt portfolio at cost, which is down 20 basis points sequentially and 250 basis points from a year ago on a cost basis. One investment came off non-accrual, one new tranche in an existing non-accrual name was added, and one new borrower was added.

BayMark came off non-accrual following the resolution by lenders to recapitalize and stabilize the business. We added the first out term loan of Pluralsight to non-accrual as the company continues to underperform expectations. As a reminder, in December 2025, we placed the second out term loan on non-accrual and marked our equity to zero. The new name added to non-accrual during this quarter is BioXcel Therapeutics, a publicly traded biopharmaceutical company, but we expect a relatively quick resolution in the December quarter. BioXcel entered Chapter 11 in late August 2026 with an up to $125 million stalking horse proposal from Teva, a large global pharmaceutical company. It was a fast-moving court-supervised process, and in late October, a sale to Teva closed at a value in line with our carrying mark of 83. Teva funded $57.5 million upfront at closing, with the balance payable upon certain regulatory and commercial thresholds.

We are pleased to say that on November 13th, Teva received FDA approval for BioXcel's drug, which has triggered the full $67.5 million additional milestone to the lenders. This is expected to be paid within 30 days and will lead to a realized value well in excess of our carrying mark. Closing out the discussion on non-accruals is an update on Praxio. As a reminder, last quarter, 80% of the debt was paid down, and the small amount that remained was returned to accrual status. In early November, the balance was fully paid down at par. Looking at total portfolio metrics as of September 30th, 79.1% of the portfolio at fair value was first lien senior secured debt. Weighted average yield on debt investments was 9.4%, compared with 9.3% last quarter. The portfolio remains well-diversified, with 170 portfolio companies.

The average debt position is approximately 62 basis points of the total portfolio at fair value, and no single position exceeds 2.1%. The median EBITDA for portfolio companies was approximately $180 million. Portfolio company weighted average leverage was 5.1 times, and the interest coverage was 2.3 times. Both metrics steady sequentially and compared to a year ago. On software, based on GICS industry group classification, software represents 20% of the portfolio at fair value, steady sequentially and down from 24% a year ago. 94% of our software positions are first lien, and ARR-based loans represent just 0.8% of the portfolio. Our high AI risk software exposure remains relatively unchanged at approximately 3% of the performing debt portfolio. With that, I will turn the call over to Chris to review our financial results.

Chris McKown
CFO and Treasurer, OCSL

Thank you, Raghav. In our fourth fiscal quarter ended September 30, 2026, adjusted total investment income was $68.0 million, down from $69.2 million in the prior quarter. The sequential decrease primarily reflected a lower average portfolio balance. Fiscal year adjusted total investment income was $281.4 million, compared with $315.4 million in the prior year. The year-over-year decrease was primarily attributable to lower reference rates and a lower average portfolio balance. The year-over-year decrease was primarily attributable to lower reference rates and a lower average portfolio balance. We delivered adjusted net investment income of $29.6 million, or $0.34 per share, compared with $32.2 million, or $0.37 per share, in the prior quarter. The sequential decline was driven by lower total investment income and a higher income-based, or Part I incentive fee, partially offset by lower interest and other expenses.

For the full year, adjusted net investment income was $131.7 million, or $1.49 per share, compared with $151 million, or $1.76 per share, in fiscal 2025, with similar performance drivers as the quarterly results. On the incentive fee, we paid $4.8 million this quarter, or approximately $0.05 per share, compared with $2.4 million last quarter, or $0.03 per share. A full quarterly incentive fee would have been approximately $6.0 million, so our total return hurdle reduced the fee by approximately $1.2 million, or about $0.01 per share, in the September quarter. For the full year, incentive fee paid was $8.4 million, or $0.10 per share. Over the last year, our total return hurdle reduced incentive fees by $16.1 million.

We believe the mechanism is working as designed, aligning the fees Oaktree earns with the total returns shareholders receive. Beginning in the December quarter, the September rate hike will start to flow through to net investment income. With 91% of our debt investments floating rate and 100% of our debt floating or swapped to floating, the net impact is positive, all else equal. Although resets are somewhat staggered across the portfolio, we will see the majority of the impact in our December quarter earnings, with the full effect building from there. Once fully reset, every 25 basis point increase in base rates adds a little over half a penny per share per quarter to adjusted net investment income, with a little over $0.02 per share annualized. Turning to NAV.

NAV per share was $15.63 as of September 30, down 0.4% from $15.70 in June. PIK income represented approximately 7.3% of adjusted total investment income during the quarter, down from 7.8% last quarter. Approximately 75% of total PIK income relates to investments that were structured with the option to PIK at origination. Investments generating non-cash income during the quarter are marked at a weighted average fair value of approximately 98. Our net leverage at quarter end was 1.00x, compared with 1.02x last quarter and 0.97x a year ago. Our long-term target leverage range of 0.9x to 1.25x remains unchanged. Total debt outstanding at quarter end was $1.42 billion. As of September 30, the weighted average interest rate on debt outstanding was 6.2%, compared with 5.9% last quarter and 6.5% a year ago.

Adjusted for the new 2031 notes, paydown of the 2027 notes, and the higher base rate, pro forma interest rate on debt is 6.4%. Unsecured debt represented approximately 88% of total debt at quarter end, compared with 65% last quarter and 64% a year ago. Pro forma for the expected repayment of the 2027 notes, unsecured debt would have been approximately 64% of total debt at quarter end. Our liquidity was approximately $1.04 billion, including $45 million of cash and $994 million of undrawn capacity under our credit facilities. Pro forma for the repayment of the 2027 notes at maturity, liquidity would have been approximately $689 million, compared with $699 million last quarter and $695 million a year ago. Unfunded commitments, excluding those related to the JVs, were approximately $226 million. Ending with our JVs.

Together, the JVs held approximately $547 million of investments across 144 portfolio companies and generated aggregate returns on equity of approximately 11.5% during the quarter. Leverage at the JVs was 2.0 times compared to 2.1 times last quarter. With that, I'll turn the call back to the operator for Q&A.

Operator

We will now begin the question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you're muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. We have no questions at this time. I will now turn the call back to Alison for closing remarks. Opening the line again, I would like to re-prompt for questions. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. Thank you. Please stand by. Your first question comes from the line of Sean-Paul Adams with B. Riley Securities. Your line is open.

Please go ahead.

Sean Adams
Analyst, B. Riley Securities

It looks like PIK kind of trended down a little bit since the June quarter. Was that due to the restructuring, or can you guys just walk me through the portfolio changes?

Chris McKown
CFO and Treasurer, OCSL

Hey, Sean- Paul, it's Chris. Thanks for the question. Yeah, in terms of the downtick quarter-on-quarter, as just mentioned in the prepared remarks, we did move BioXcel to non-accruals. That was part of the impact. We do expect a quick resolution there. Then the other factor, we had a royalty interest that had been PIKing previosly that we exited during the quarter. Those were the two big drivers.

Sean Adams
Analyst, B. Riley Securities

Got it. Thank you for the call.

Operator

Your next question comes from the line of Ethan Kaye. with Lucid Capital Markets. Your line is open. Please go ahead.

Ethan Kaye
Analyst, Lucid Capital Markets

Hey, guys. Just a quick one for me. Can you just kind of review capital allocation priorities? You talked about, you have some room to kind of bring leverage higher if you want. You talked about remaining kind of flexible on the balance sheet, but just walk through balancing kind of deployment and repurchases and leverage, et cetera. Thanks very much.

Matt Pendo
President, OCSL

Hey, Ethan. It's Matt. Thanks for the question. We talk to the board every quarter about capital allocation. We want to be thoughtful about it. Since we took over management, we have not repurchased shares for a couple of reasons. I think the primary is just desire to have capital to continue to invest in portfolios and attractive loans that we see. That continues to be kind of priority number one. Over 2026, we ran leverage 0.97-1.07. As I mentioned on the call, our target is 0.9-1.25. We ended the year at one time, so we definitely, and as Chris kind of walked through our liquidity and capital, we have plenty of capital. So I think our primary focus is to deploy into attractive investment opportunities. We have the capital.

We're comfortable taking our leverage up within the range we've done in the last year, 0.97, 1.07. So I think that's where we're going to be focused.

Ethan Kaye
Analyst, Lucid Capital Markets

Great. And then I guess one more quick one. I think in the past, you've kind of categorized the credits that have underperformed as maybe businesses that struggled with post-COVID normalization. It looks like credit performance has stabilized nicely in the last couple of quarters. But curious if you kind of feel like the impact from that kind of trend has subsided largely, maybe with the exception of Pluralsight.

Raghav Khanna
Co-CIO, OCSL

Yeah. Hey, Sean. Hey, Ethan. I can take that. You are right. Most of the big declines in 2021 and 2022 were because of post-COVID normalizations, but also, frankly, a lot of the capital structures that were put in place in 2021 and early 2022 were just not set up for base rates being in low fours to five. Those were the primary reasons. I think going forward, and what you are seeing right now is the non-accruals. The one non-accrual that was added, the new name, it is largely because of idiosyncratic reasons. To give you some color, the name that was added, it is the largest opioid treatment center business in the U.S. When you think about the end market, it is not cyclical, and frankly, the revenues have not been cycling.

They had an idiosyncratic issue in revenue collection because of bad ERP systems, which is what led to the restructuring. When we see problems in the portfolio now, they are idiosyncratic as opposed to because of one big theme.

Ethan Kaye
Analyst, Lucid Capital Markets

Great. Yeah, that was the crux of my question. Thanks very much.

Matt Pendo
President, OCSL

Ethan, just to follow up, I do think, and we talked about it on the call, like the progress in BioXcel, I still think there is progress we can make on the existing non-accruals.

Operator

We have reached the end of the Q&A session. I will now turn the call back to Alison for closing remarks.

Alison Mermey
Head of Investor Relations, OCSL

Thank you all for joining us on today's call. Please feel free to reach out to me and the team with any questions. Have a great day, everyone.

Operator

This concludes today's call. Thank you for attending. You may now disconnect.